Anti-inflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib

Journal of Pharmacology and Experimental Therapeutics

Volumn 317, Issue 1, 2006, Pages 53-60

  Xue, Xiaohua ^a   Lai, Kuei Tai A ^a   Huang, Jing Feng ^a   Gu, Yin ^a   Karlsson, Lars ^a   Fourie, Anne ^a,b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; STAT1 PROTEIN; TIPIFARNIB; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INFLAMMATION; LEUKEMIA CELL LINE; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE, TUMOR; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FARNESYLTRANSTRANSFERASE; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICROARRAY ANALYSIS; QUINOLONES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 33645131233     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.095976     Document Type: Article

References (24)

1. Aggarwal B (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3:745-756.
2. Akira S and Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:499-511.
3. Balkwill F, Charles KA, and Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211-217.
4. Caunt CJ, Kiss-Toth E, Carlotti F, Chapman R, and Qwarnstrom EE (2001) Ras controls tumor necrosis factor receptor-associated factor (TRAF)6-dependent induction of nuclear factor-κB. Selective regulation through receptor signaling components. J Biol Chem 276:6280-6288.
5. Cortes J (2003) Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma 4:S30-S35.
6. Cox AD and Der CJ (1997) Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta 1333:F51-F71.
7. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, et al. (2001) Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131-137.
8. Head JE and Johnston SR (2003) Protein farnesyltransferase inhibitors. Expert Opin Emerg Drugs 8:163-178.
9. Jenkins CM, Han X, Yang J, Mancuso DJ, Sims HF, Muslin AJ, and Gross RW (2003) Purification of recombinant human cPLA2 gamma and identification of C-terminal farnesylation, proteolytic processing and carboxymethylation by MALDI-TOF-TOF analysis. Biochemistry 42:11798-11807.
10. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, et al. (2001) Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97:3361-3369.
11. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, and Der CJ (1992) Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89:6403-6407.
12. Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M, and Sebti SM (2003) Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 102:4527-4534.
13. Moores SL, Schaber MD, Mosser SD, Rands E, O'Hara MB, Garsky VM, Marshall MS, Pompliano DL, and Gibbs JB (1991) Sequence dependence of protein isoprenylation. J Biol Chem 266:14603-14610.
14. Na HJ, Lee SJ, Kang YC, Cho YL, Nam WD, Kim PK, Ha KS, Chung HT, Lee H, Kwon YG, et al. (2004) Inhibition of farnesyltransferase prevents collagen-induced arthritis by down-regulation of inflammatory gene expression through suppression of p21(ras)-dependent NF-kappaB activation. J Immunol 173:1276-1283.
15. O'Meara SJ and Kinsella BT (2004) Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor. Br J Pharmacol 143:318-330.
16. O'Meara SJ and Kinsella BT (2005) The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor. Biochem J 386:177-189.
17. Peterson KS, Huang JF, Zhu J, D'Agati V, Liu X, Miller N, Erlander MG, Jackson MR, and Winchester RJ (2004) Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Investig 113:1722-1733.
18. Reiss Y, Stradley SJ, Gierasch LM, Brown MS, and Goldstein JL (1991) Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. Proc Natl Acad Sci USA 88:732-736.
19. Schafer WR and Rine J (1992) Protein prenylation: genes, enzymes, targets and functions. Annu Rev Genet 26:209-237.
20. Sebti SM and Hamilton AD (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-tobedside translational studies. Oncogene 19:6584-6593.
21. Shaw KJ, Miller N, Liu X, Lerner D, Wan J, Bittner A, and Morrow BJ (2003) Comparison of the changes in global gene expression of Escherichia coli induced by four bactericidal agents. J Mol Microbiol Biotechnol 5:105-122.
22. Takada Y, Khuri FR, and Aggarwal BB (2004) Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis. J Biol Chem 279:26287-26299.
23. Tamanoi F, Kato-Stankiewicz J, Jiang C, Machado I, and Thapar N (2001) Farnesylated proteins and cell cycle progression. J Cell Biochem Suppl 37:64-70.
24. Xu H, An H, Yu Y, Zhang M, Qi R, and Cao X (2003) Ras participates in CpG oligodeoxynucleotide signaling through association with toll-like receptor 9 and promotion of interleukin-1 receptor-associated kinase/tumor necrosis factor receptor-associated factor 6 complex formation in macrophages. J Biol Chem 278:36334-36440.